QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease stat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CALDWELL, JOHN, P, KELLEY, ELIZABETH HELEN, SILIPHAIVANH, PHIENG, ZHOU, WEI, QIN, JUN, ZHANG, HONGJUN, MACCOSS, RACHEL, N, METHOT, JOEY, L, ASLANIAN, ROBERT, G, MAZZOLA, ROBERT, D., JR, BIJU, PURAKKATTLE JOHNY, YU, YOUNONG, DONG, LI, BOYCE, CHRISTOPHER, W, MCKITTRICK, BRIAN, A, XIAO, DONG, GAUUAN, JOLICIA POLIVINA, TANG, HAIQUN, HUANG, XIANHAI, PALANI, ANANDAN, LEYHANE, ANDREW, J, MCCORMICK, KEVIN, D, SHAO, NING, JIANG, QIN, DHONDI, PAWAN, K
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	AGRICULTURE ANIMAL HUSBANDRY BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES CHEMISTRY FISHING FORESTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HUNTING METALLURGY ORGANIC CHEMISTRY PEST REPELLANTS OR ATTRACTANTS PLANT GROWTH REGULATORS PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF TRAPPING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor. La présente invention concerne des composés représentés par la formule (I), ou l'un de ses sels pharmaceutiquement admis, les différentes variables de cette formule étant telles que définies dans les spécifications. L'invention concerne également des procédés d'élaboration de ces composés, des compositions pharmaceutiques comprenant ces composés, et leur utilisation pour le traitement d'un état pathologique associé au récepteur du CRTH2.